Hypothesis Comparison

⚛ Collide these

Comparing 1 hypotheses side-by-side

|

Microglial Reactivation Status Modifies Amyloid Clearance and p-tau217 Normaliza

TREM2 · neurodegeneration · -
Composite
0.524
Price
$0.51
Evidence For
0
Evidence Against
0

Donanemab triggers acute microglial activation (ARIA-E). Patients achieving favorable M2-like phenotype show better p-tau217 normalization due to enhanced tau aggregate clearance, while persistent M1 phenotype may show biomarker dissociation. However, TSPO-PET M1/M2 specificity in humans is questionable—human microglia do not conform cleanly to the rodent M1/M2 dichotomy, and TSPO signals are non-specific for activation state.

Radar Chart — 10 Dimensions

Score Comparison Bars

Mechanistic
0.52
Evidence
0.45
Novelty
0.62
Feasibility
0.42
Impact
0.55
Druggability
0.45
Safety
0.58
Competition
0.75
Data
0.48
Reproducible
0.42
KG Connect
0.53

Score Breakdown

DimensionMicroglial Reactivation Status
Mechanistic0.520
Evidence0.450
Novelty0.620
Feasibility0.420
Impact0.550
Druggability0.450
Safety0.580
Competition0.750
Data0.480
Reproducible0.420
KG Connect0.533

Evidence

Microglial Reactivation Status Modifies Amyloid Clearance an

No evidence citations yet

Price History Overlay